Trial · NCT00103311

SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT00103311, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2015-03-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer. Trials, record NCT00103311. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00103311

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT number: NCT00103311
Status: Completed
Phases: Phase 2
Enrollment: 64 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: ispinesib, laboratory biomarker analysis
First posted: 2005-02-08
Last updated: 2015-03-02
Results first posted: 2015-03-02

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Objective Response (CR or PR) as Determined by the RECIST Criteria	Up to 5 years	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Secondary	Progression-free Survival	From the date of registration to the date of documented PSA progression, assessed up to 6 months	Will be estimated using the product-limit method of Kaplan and Meier by arm. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Secondary	Overall Survival	From the date of registration to the date of death, assessed up to 12 months	Will be estimated using the product-limit method of Kaplan and Meier by arm.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Objective Response (CR or PR) as Determined by the RECIST Criteria	Up to 5 years	participants	NUMBER
SECONDARY	Progression-free Survival	From the date of registration to the date of documented PSA progression, assessed up to 6 months	weeks	MEDIAN
SECONDARY	Overall Survival	From the date of registration to the date of death, assessed up to 12 months	months	MEDIAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Objective Response (CR or PR) as Determined by the RECIST Criteria	Arm I	0		participants
Objective Response (CR or PR) as Determined by the RECIST Criteria	Arm II	0		participants
Progression-free Survival	Arm I	7.0	95% Confidence Interval 6.3 to 7.3	weeks
Progression-free Survival	Arm II	5.3	95% Confidence Interval 5.0 to 5.9	weeks
Overall Survival	Arm I	3.6	95% Confidence Interval 2.5 to 8.2	months
Overall Survival	Arm II	4.5	95% Confidence Interval 3.7 to 7.0	months

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm I	33
Overall Study	STARTED	Arm II	31
Overall Study	COMPLETED	Arm I	29
Overall Study	COMPLETED	Arm II	30
Overall Study	NOT COMPLETED	Arm I	4
Overall Study	NOT COMPLETED	Arm II	1

Source ClinicalTrials.gov

Adverse events268

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hemoglobin decreased	Blood and lymphatic system disorders	Arm I	17	33	23
other	Hemoglobin decreased	Blood and lymphatic system disorders	Arm II	18	31	29
other	Hemolysis	Blood and lymphatic system disorders	Arm I	0	33	0
other	Hemolysis	Blood and lymphatic system disorders	Arm II	1	31	2
other	Atrial fibrillation	Cardiac disorders	Arm I	1	33	1
other	Atrial fibrillation	Cardiac disorders	Arm II	0	31	0
other	Flashing vision	Eye disorders	Arm I	0	33	0
other	Flashing vision	Eye disorders	Arm II	1	31	1
other	Vision blurred	Eye disorders	Arm I	0	33	0
other	Vision blurred	Eye disorders	Arm II	1	31	1

1 to 10 of 268Source ClinicalTrials.gov

See all 268 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Arm I
Total, all-cause mortality	Arm II
Total, other adverse events	Arm I	33	33
Total, other adverse events	Arm II	31	31
Total, serious adverse events	Arm I	14	33
Total, serious adverse events	Arm II	13	31

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Arm I vs Arm II: Objective Response (CR or PR) as Determined by the RECIST Criteria	Trial comparisons
Arm I vs Arm II: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00103311

GET https://conductscience.org/api/trials/v1/NCT00103311/events?page=2

API reference For AI assistants